Disclaimer: PT-141 (Bremelanotide) is sold strictly for laboratory research purposes only. While an approved medication (Vyleesi) exists, the research peptide form is not intended for human consumption or animal use. This article discusses published scientific research and does not constitute medical advice.
Understanding PT-141
PT-141, also known as bremelanotide, is a synthetic peptide analogue of alpha-melanocyte stimulating hormone (α-MSH). Originally developed from the tanning peptide Melanotan II, PT-141 was found to exhibit distinct effects on sexual arousal through melanocortin receptor pathways in the central nervous system. The compound received FDA approval in 2019 under the brand name Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women (Dhillon & Keam, 2019).
Unlike phosphodiesterase-5 (PDE5) inhibitors that work through vascular mechanisms, PT-141 acts centrally on melanocortin receptors, particularly MC3R and MC4R, which are involved in sexual motivation and arousal pathways.
Mechanism of Action
PT-141’s pharmacology involves several key pathways:
Melanocortin Receptor Activation: Bremelanotide selectively activates MC3R and MC4R in hypothalamic regions associated with sexual behavior, without significant MC1R activation (which mediates tanning effects). A comprehensive neurobiology review published in CNS Spectrums demonstrated that bremelanotide affects sexual desire by activating presynaptic MC4Rs on neurons in the medial preoptic area (mPOA) of the hypothalamus, leading to increased dopamine release (Pfaus et al., 2022).
Central Nervous System Effects: The same neurobiology research confirmed that bremelanotide administration increases activity in brain regions associated with reward and motivation, including the nucleus accumbens and medial preoptic area, through dopaminergic neurotransmission pathways.
Neurotransmitter Modulation: Melanocortin receptor activation by PT-141 influences dopaminergic and oxytocinergic neurotransmission, both implicated in sexual arousal and social bonding. This central mechanism distinguishes PT-141 from peripherally-acting compounds.
Distinct from Vascular Mechanisms: Unlike PDE5 inhibitors, PT-141 does not require intact vascular function. Earlier clinical research demonstrated that bremelanotide could produce erectile responses even in patients who did not respond adequately to sildenafil, suggesting the value of a centrally-acting mechanism (Diamond et al., 2008).
PT-141 is supplied as a research peptide for laboratory investigation only. It is not intended for human consumption, and all references to clinical studies describe findings from controlled research settings.
Clinical Research Findings
Several large-scale clinical trials have investigated bremelanotide (Vyleesi formulation) in women with hypoactive sexual desire disorder (HSDD):
The RECONNECT trials, published in 2019 in Obstetrics & Gynecology, were two randomized, double-blind, placebo-controlled phase 3 studies evaluating bremelanotide 1.75 mg administered subcutaneously as needed. Both studies demonstrated statistically significant improvements in sexual desire scores (FSFI-desire domain) and reductions in distress related to low sexual desire (FSDS-DAO) compared to placebo (Kingsberg et al., 2019).
Subsequent subgroup analyses from the RECONNECT studies, published in the Journal of Women’s Health in 2022, confirmed that bremelanotide produced statistically significant improvements across multiple prespecified demographic and clinical subgroups, including various age ranges, BMI categories, and HSDD durations (Simon et al., 2022).
A RECONNECT exit study published in the Journal of Women’s Health in 2021 evaluated the patient experience, finding that participants receiving bremelanotide described increased feelings of sexual desire, physical arousal, and improvements in overall quality of their sexual activities (Koochaki et al., 2021).
Subcutaneous injection: Clinical trials used 1.75 mg administered 45 minutes before anticipated sexual activity
Intranasal (earlier research): Studies examined doses from 7-20 mg, though this route showed variable bioavailability
Frequency: Clinical protocols limited use to no more than 8 doses per month
Onset: Effects typically observed within 30-60 minutes, lasting 4-6 hours
Note: FDA-approved Vyleesi follows specific dosing guidelines. Research peptide PT-141 is sold for laboratory research purposes only and is not approved for human use.
Safety Profile and Side Effects
Clinical trial safety data provides insight into the compound’s tolerability:
The most commonly reported side effects in the RECONNECT trials were nausea (occurring in approximately 40% of subjects vs. 13% placebo), facial flushing (20% vs. 2% placebo), and headache (11%). A comprehensive pharmacotherapy evaluation published in Expert Opinion on Pharmacotherapy in 2023 concluded that bremelanotide appears moderately safe and well-tolerated, with nausea typically mild-to-moderate and decreasing with repeated use (Cipriani et al., 2023).
Transient blood pressure increases were observed in some participants, leading to screening requirements for cardiovascular risk factors. FDA labeling notes that bremelanotide transiently increases blood pressure and reduces heart rate after each dose, with these changes typically resolving within 12 hours. Patients with uncontrolled hypertension or significant cardiovascular disease were excluded from clinical trials.
Skin hyperpigmentation, a concern with earlier melanocortin analogues like Melanotan II, was minimal with PT-141 due to reduced MC1R activity. Clinical dosing at the approved 1.75 mg subcutaneous dose showed no significant tanning effects.
Current Research Directions
Ongoing investigations are exploring several promising areas:
Applications in postmenopausal women with sexual dysfunction
Combination approaches with PDE5 inhibitors for male erectile dysfunction — Palatin Technologies initiated a Phase II clinical program evaluating bremelanotide co-formulated with a PDE5 inhibitor for men who are non-responsive to PDE5 inhibitors alone
Long-term efficacy and safety beyond one-year use
Potential role in male sexual dysfunction of various etiologies, including psychogenic erectile dysfunction
Neuroimaging studies to better understand central mechanisms
Alternative formulations to reduce nausea incidence
All ongoing and future research involving PT-141 as a research peptide is conducted under appropriate laboratory protocols. This compound is not intended for human consumption outside of approved clinical settings.
Research comparing melanocortin agonists to other interventions has highlighted important distinctions:
A review published in Annals of Pharmacotherapy compared PT-141 to flibanserin (another HSDD treatment), noting distinct mechanisms and side effect profiles. PT-141 showed faster onset as an as-needed therapy but higher nausea rates, while flibanserin required daily dosing but had lower acute side effects (Mayer & Lynch, 2020).
Earlier clinical research with PDE5 inhibitors in male subjects suggested potential synergistic effects when combined with bremelanotide, as the compounds work through fundamentally different pathways — one central and one peripheral. This concept is now being explored in the ongoing Palatin Technologies Phase II co-formulation trial.
Conclusion
PT-141 represents a unique pharmacological approach to sexual dysfunction research, acting centrally through melanocortin receptors rather than peripheral vascular mechanisms. Clinical research has demonstrated efficacy in female HSDD with a well-characterized safety profile dominated by nausea and flushing.
The compound’s development from research peptide to FDA-approved medication (as Vyleesi) illustrates the translational pathway from laboratory to clinical application. However, the research peptide form remains strictly for laboratory investigation and is not intended for human or animal use.
Future research will likely focus on optimizing formulations to reduce side effects, identifying patient populations most likely to benefit, and exploring potential applications in male sexual dysfunction and other conditions involving melanocortin pathways.
Verified Research References:
Kingsberg SA, et al. “Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.” Obstet Gynecol. 2019;134(5):899-908. PMID: 31599840
Pfaus JG, et al. “The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women.” CNS Spectr. 2022;27(3):281-289. PMID: 33455598
Simon JA, et al. “Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.” J Womens Health. 2022;31(3):391-400. PMID: 35230162
Koochaki P, et al. “The Patient Experience of Premenopausal Women Treated with Bremelanotide for HSDD: RECONNECT Exit Study Results.” J Womens Health. 2021;30(4):587-595. PMID: 33538638
Cipriani S, et al. “An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder.” Expert Opin Pharmacother. 2023;24(1):73-83. PMID: 36242769
Mayer D, Lynch SE. “Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder.” Ann Pharmacother. 2020;54(7):684-690. PMID: 31893927
Diamond LE, et al. “Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study.” J Sex Med. 2008;5(3):575-584. PMID: 18206919
Research peptides are intended for laboratory research use only. Not for human or animal consumption. Consult healthcare providers for medical concerns.
Epithalon, a leading telomere peptide, is making waves in anti-aging research for its impressive ability to support telomere health and rejuvenate cells from within. Discover how epithalon could be key to unlocking a more youthful you.
Peptide toxicity research has become an increasingly important area of scientific investigation as researchers seek to understand the safety margins of these bioactive compounds. For scientists working with peptides in laboratory settings, understanding toxicity thresholds and safety profiles is essential for designing appropriate research protocols. This comprehensive review examines what current scientific literature reveals about …
PT-141 (Bremelanotide): Research on Melanocortin Receptor Agonism and Sexual Function
Disclaimer: PT-141 (Bremelanotide) is sold strictly for laboratory research purposes only. While an approved medication (Vyleesi) exists, the research peptide form is not intended for human consumption or animal use. This article discusses published scientific research and does not constitute medical advice.
Understanding PT-141
PT-141, also known as bremelanotide, is a synthetic peptide analogue of alpha-melanocyte stimulating hormone (α-MSH). Originally developed from the tanning peptide Melanotan II, PT-141 was found to exhibit distinct effects on sexual arousal through melanocortin receptor pathways in the central nervous system. The compound received FDA approval in 2019 under the brand name Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women (Dhillon & Keam, 2019).
Unlike phosphodiesterase-5 (PDE5) inhibitors that work through vascular mechanisms, PT-141 acts centrally on melanocortin receptors, particularly MC3R and MC4R, which are involved in sexual motivation and arousal pathways.
Mechanism of Action
PT-141’s pharmacology involves several key pathways:
PT-141 is supplied as a research peptide for laboratory investigation only. It is not intended for human consumption, and all references to clinical studies describe findings from controlled research settings.
Clinical Research Findings
Several large-scale clinical trials have investigated bremelanotide (Vyleesi formulation) in women with hypoactive sexual desire disorder (HSDD):
The RECONNECT trials, published in 2019 in Obstetrics & Gynecology, were two randomized, double-blind, placebo-controlled phase 3 studies evaluating bremelanotide 1.75 mg administered subcutaneously as needed. Both studies demonstrated statistically significant improvements in sexual desire scores (FSFI-desire domain) and reductions in distress related to low sexual desire (FSDS-DAO) compared to placebo (Kingsberg et al., 2019).
Subsequent subgroup analyses from the RECONNECT studies, published in the Journal of Women’s Health in 2022, confirmed that bremelanotide produced statistically significant improvements across multiple prespecified demographic and clinical subgroups, including various age ranges, BMI categories, and HSDD durations (Simon et al., 2022).
A RECONNECT exit study published in the Journal of Women’s Health in 2021 evaluated the patient experience, finding that participants receiving bremelanotide described increased feelings of sexual desire, physical arousal, and improvements in overall quality of their sexual activities (Koochaki et al., 2021).
Dosage in Research and Clinical Studies
Published protocols vary by administration route:
Note: FDA-approved Vyleesi follows specific dosing guidelines. Research peptide PT-141 is sold for laboratory research purposes only and is not approved for human use.
Safety Profile and Side Effects
Clinical trial safety data provides insight into the compound’s tolerability:
The most commonly reported side effects in the RECONNECT trials were nausea (occurring in approximately 40% of subjects vs. 13% placebo), facial flushing (20% vs. 2% placebo), and headache (11%). A comprehensive pharmacotherapy evaluation published in Expert Opinion on Pharmacotherapy in 2023 concluded that bremelanotide appears moderately safe and well-tolerated, with nausea typically mild-to-moderate and decreasing with repeated use (Cipriani et al., 2023).
Transient blood pressure increases were observed in some participants, leading to screening requirements for cardiovascular risk factors. FDA labeling notes that bremelanotide transiently increases blood pressure and reduces heart rate after each dose, with these changes typically resolving within 12 hours. Patients with uncontrolled hypertension or significant cardiovascular disease were excluded from clinical trials.
Skin hyperpigmentation, a concern with earlier melanocortin analogues like Melanotan II, was minimal with PT-141 due to reduced MC1R activity. Clinical dosing at the approved 1.75 mg subcutaneous dose showed no significant tanning effects.
Current Research Directions
Ongoing investigations are exploring several promising areas:
All ongoing and future research involving PT-141 as a research peptide is conducted under appropriate laboratory protocols. This compound is not intended for human consumption outside of approved clinical settings.
Comparison with Other Approaches
Research comparing melanocortin agonists to other interventions has highlighted important distinctions:
A review published in Annals of Pharmacotherapy compared PT-141 to flibanserin (another HSDD treatment), noting distinct mechanisms and side effect profiles. PT-141 showed faster onset as an as-needed therapy but higher nausea rates, while flibanserin required daily dosing but had lower acute side effects (Mayer & Lynch, 2020).
Earlier clinical research with PDE5 inhibitors in male subjects suggested potential synergistic effects when combined with bremelanotide, as the compounds work through fundamentally different pathways — one central and one peripheral. This concept is now being explored in the ongoing Palatin Technologies Phase II co-formulation trial.
Conclusion
PT-141 represents a unique pharmacological approach to sexual dysfunction research, acting centrally through melanocortin receptors rather than peripheral vascular mechanisms. Clinical research has demonstrated efficacy in female HSDD with a well-characterized safety profile dominated by nausea and flushing.
The compound’s development from research peptide to FDA-approved medication (as Vyleesi) illustrates the translational pathway from laboratory to clinical application. However, the research peptide form remains strictly for laboratory investigation and is not intended for human or animal use.
Future research will likely focus on optimizing formulations to reduce side effects, identifying patient populations most likely to benefit, and exploring potential applications in male sexual dysfunction and other conditions involving melanocortin pathways.
Verified Research References:
Research peptides are intended for laboratory research use only. Not for human or animal consumption. Consult healthcare providers for medical concerns.
Related Posts
Epithalon & Telomere Peptide: Stunning Benefits for Anti-Aging
Epithalon, a leading telomere peptide, is making waves in anti-aging research for its impressive ability to support telomere health and rejuvenate cells from within. Discover how epithalon could be key to unlocking a more youthful you.
Peptide Toxicity Research: Safety Margins & Study Findings
Peptide toxicity research has become an increasingly important area of scientific investigation as researchers seek to understand the safety margins of these bioactive compounds. For scientists working with peptides in laboratory settings, understanding toxicity thresholds and safety profiles is essential for designing appropriate research protocols. This comprehensive review examines what current scientific literature reveals about …